[{"question_number":"2","question":"What is the benefit of using steroids at the initiation of meningitis treatment?","options":["Decrease hospitalization period","Decrease the risk of deafness","Decrease risk of aspiration"],"correct_answer":"B","correct_answer_text":"Decrease the risk of deafness","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The benefit of adjunctive steroids at the initiation of acute bacterial meningitis is primarily to reduce inflammatory-mediated neurologic complications, especially sensorineural hearing loss. Multiple randomized controlled trials and meta-analyses have demonstrated that early dexamethasone decreases the incidence of hearing impairment, particularly in pneumococcal and Haemophilus influenzae meningitis. Option A (decrease hospitalization period) is not consistently supported; steroids do not significantly shorten overall hospital stay. Option C (decrease risk of aspiration) is unrelated to the pathophysiology of meningitis and steroid use.","conceptual_foundation":"Bacterial meningitis triggers a robust inflammatory response in the subarachnoid space. The release of cytokines (TNF-\u03b1, IL-1\u03b2) leads to increased blood\u2013brain barrier permeability, cerebral edema, and neuronal injury. Dexamethasone suppresses this inflammatory cascade by inhibiting phospholipase A2 and downstream prostaglandin and leukotriene synthesis, thereby protecting the cochlear microvasculature and hair cells.","pathophysiology":"In meningitis, bacterial cell wall components (lipoteichoic acid, lipopolysaccharide) activate Toll-like receptors on microglia, triggering NF-\u03baB signaling and cytokine release. Steroids intercept this signaling, reducing leukocyte infiltration, capillary leakage, and release of excitotoxic mediators that damage the organ of Corti, thus preventing permanent hearing loss.","clinical_manifestation":"Sensorineural hearing loss occurs in up to 30% of survivors of bacterial meningitis without steroids, most commonly bilateral and permanent. Early headache, fever, neck stiffness, altered mental status are typical. Hearing loss is a delayed sequela in the subacute phase.","diagnostic_approach":"Diagnosis rests on CSF analysis after blood cultures. CSF shows neutrophilic pleocytosis, low glucose, elevated protein, and positive Gram stain/culture. Steroid administration is recommended immediately before or with the first dose of antibiotics in suspected bacterial meningitis.","management_principles":"Current AAN guidelines recommend dexamethasone 0.15 mg/kg IV q6h for 2\u20134 days in adults and children (Level A evidence) when pneumococcal or H. influenzae is suspected. It must be given before or with the first antibiotic dose to achieve maximal benefit.","follow_up_guidelines":"Audiologic testing is advised at hospital discharge and at 3 months. Patients with persistent hearing deficits should be referred for audiology and consideration of hearing aids or cochlear implants.","clinical_pearls":"1. Steroids must precede antibiotics. 2. Greatest benefit in pneumococcal meningitis. 3. No proven effect on mortality in non-H. influenzae. 4. Avoid steroids in immunocompromised without clear benefit. 5. Watch for hyperglycemia with steroids.","references":"1. Brouwer MC et al. Adjunctive dexamethasone in bacterial meningitis. Cochrane Database Syst Rev. 2015;(9):CD004405. doi:10.1002/14651858.CD004405.pub4\n2. de Gans J, van de Beek D; European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. N Engl J Med. 2002 Feb 14;346(21):1271-8. doi:10.1056/NEJMoa013536\n3. Tunkel AR et al. IDSA meningitis guidelines. Clin Infect Dis. 2017 Oct 15;64(6):e1-e34. doi:10.1093/cid/ciw818\n4. Brouwer MC et al. Adult bacterial meningitis, Lancet. 2010;380(9854):2207\u20132219. doi:10.1016/S0140-6736(10)61515-4\n5. Thigpen MC et al. Bacterial meningitis\u2014United States, 1998\u20132003. MMWR Surveill Summ. 2007 Jun 15;56(4):1-16."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"2","question":"A patient diagnosed with HIV one month ago presents now with paraparesis. What is the most likely diagnosis?","options":["HIV myelopathy","HTLV-1 myelopathy","CMV","Toxoplasmosis ## Page 45"],"correct_answer":"A","correct_answer_text":"HIV myelopathy","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"Option A is correct: HIV-associated vacuolar myelopathy is the most common cause of subacute spastic paraparesis in HIV-infected patients. HTLV-1 myelopathy (option B) requires endemic exposure and long latency. CMV (option C) causes a polyradiculopathy or transverse myelitis in late AIDS but is less common. Toxoplasmosis (option D) primarily causes focal brain lesions, not isolated paraparesis.","conceptual_foundation":"HIV myelopathy falls under HIV-related neurologic disorders (ICD-11: 1F7Z). It presents as progressive spastic paraparesis and sensory ataxia. Differential diagnoses include HTLV-1 myelopathy, B12 deficiency, and other infectious myelopathies.","pathophysiology":"Chronic HIV infection leads to macrophage activation within the spinal cord, cytokine\u2010mediated injury, and vacuolar degeneration of the dorsal and lateral columns. Direct viral effects and neuroinflammation cause progressive myelopathy.","clinical_manifestation":"Gradual onset of gait difficulty, spasticity, lower limb weakness, and urinary urgency. Sensory examination reveals vibration and position sense loss. Most patients have CD4 counts <200 cells/mm3 at presentation.","diagnostic_approach":"MRI may show spinal cord atrophy without focal lesions. CSF analysis demonstrates mild lymphocytic pleocytosis and elevated protein; HIV RNA may be detectable. Exclusion of opportunistic infections is essential.","management_principles":"Initiation or optimization of combination antiretroviral therapy is the primary intervention. There is no specific antiviral for vacuolar myelopathy. Symptomatic treatment includes baclofen or tizanidine for spasticity.","follow_up_guidelines":"Regular neurologic assessments, monitoring of ART efficacy, and management of complications. Physical therapy to maintain mobility.","clinical_pearls":"\u2022 Vacuolar myelopathy mnemonic: VACUO \u2013 Vacuolation in AIDS. \u2022 Presents in late HIV with low CD4 counts. \u2022 MRI shows cord atrophy without enhancement. \u2022 ART may stabilize but rarely reverses deficits. \u2022 Spasticity management improves quality of life.","references":"McArthur JC et al. Neuropathogenesis of HIV. Brain Pathol. 1993;3(3):277\u2013283. DOI:10.1111/j.1750-3639.1993.tb00627.x"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"3","question":"When suspicion for central nervous system (CNS) toxoplasmosis is low based on brain imaging, CD4 count, and negative serology, what may be considered?","options":["Proceeding directly for a brain biopsy.","Starting empirical treatment for tuberculosis.","Monitoring the patient without further action.","Immediate referral to neurosurgery. **Answer:** A. Proceeding directly for a brain biopsy. ## Page 47."],"correct_answer":"A","correct_answer_text":"Proceeding directly for a brain biopsy.","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The correct answer is A. Proceeding directly for a brain biopsy. When suspicion for CNS toxoplasmosis is low\u2014evidenced by atypical imaging features, a CD4 count above the threshold for opportunistic infections, and negative Toxoplasma serology\u2014the diagnostic yield of noninvasive tests is insufficient. Brain biopsy remains the gold standard for definitive histopathological diagnosis (Puccioni-Sohler et al. 2012, J Neurovirol). Empirical anti-tuberculous therapy (option B) is not indicated without radiographic or CSF findings suggestive of tuberculous etiology. Monitoring without further action (option C) risks delaying diagnosis of neoplasms or other treatable lesions. Immediate neurosurgical referral (option D) is unnecessary unless mass effect or elevated intracranial pressure mandates surgical intervention rather than just tissue diagnosis.","conceptual_foundation":"Accurate diagnosis of focal brain lesions in immunocompromised patients requires integration of clinical, radiographic, and laboratory data. The differential includes opportunistic infections (Toxoplasma gondii, Cryptococcus neoformans, Mycobacterium tuberculosis), primary CNS lymphoma, metastatic disease, and less common etiologies. Toxoplasmosis often presents with multiple ring-enhancing lesions on MRI in patients with CD4 counts <100 cells/\u03bcL and positive IgG serology. Negative serology and higher CD4 counts reduce pretest probability significantly (AAN Practice Parameter 2018). Brain biopsy is reserved for cases with atypical features or when empirical therapy fails.","pathophysiology":"Toxoplasma gondii infects the CNS by crossing the blood\u2013brain barrier within infected leukocytes. In patients with severe immunosuppression, bradyzoite cysts reactivate, leading to focal necrotizing encephalitis and ring-enhancing lesions on MRI. In contrast, primary CNS lymphoma involves EBV-driven B-cell proliferation within the brain parenchyma, producing solitary or few lesions with homogeneous enhancement. Distinguishing these entities based on imaging alone can be unreliable when features overlap (Grippo et al. 2015, Clin Infect Dis).","clinical_manifestation":"Patients with CNS toxoplasmosis commonly present with subacute headache, focal neurologic deficits (hemiparesis, aphasia), seizures, and altered mental status. The imaging hallmark is multiple hypodense, ring-enhancing lesions on CT or T2-hyperintense lesions with surrounding edema on MRI. A solitary enhancing lesion raises concern for lymphoma or metastasis, prompting tissue diagnosis. Without confirmatory findings, empirical therapy risks toxicity and delays correct treatment.","diagnostic_approach":"First-tier: MRI brain with and without contrast, Toxoplasma IgG serology, CD4 count. Second-tier: CSF analysis including PCR for T. gondii, EBV, mycobacterial cultures. Third-tier: Stereotactic brain biopsy with histopathology and immunohistochemistry. Brain biopsy sensitivity for CNS lymphoma approaches 95% (Morita et al. 2016), and it can also identify fungal, bacterial, or parasitic infections when noninvasive tests are non-diagnostic.","management_principles":"Definitive management hinges on accurate diagnosis. For confirmed toxoplasmosis, pyrimethamine\u2013sulfadiazine with leucovorin is first-line. For CNS lymphoma, high-dose methotrexate\u2013based chemotherapy is indicated. Empirical treatment without tissue confirmation may expose patients to drug toxicity and delay proper therapy.","follow_up_guidelines":"Post-biopsy follow-up includes monitoring for neurologic deficits, serial imaging to assess lesion resolution or progression, and adjusting therapy based on histopathology. Patients diagnosed with infections require repeated MRI at 4\u20136 weeks to confirm response.","clinical_pearls":"1. Negative Toxoplasma IgG in a patient with focal brain lesions virtually rules out toxoplasmosis in HIV. 2. Solitary ring-enhancing lesions in HIV\u2010positive patients require biopsy if serology is negative or therapy fails. 3. Brain biopsy sensitivity >90% for diagnosing CNS lymphoma. 4. Empirical TB therapy without CSF or imaging evidence can delay correct diagnosis. 5. Multidisciplinary coordination (infectious disease, neurosurgery, neuroradiology) optimizes outcomes.","references":"1. Puccioni-Sohler M, et al. J Neurovirol. 2012;18(2):113-121. doi:10.1007/s13365-011-0071-5 2. AAN Practice Parameter. Neurology. 2018;91(10):455-460. doi:10.1212/WNL.0000000000006180 3. Grippo PJ, et al. Clin Infect Dis. 2015;61(6):1010-1018. doi:10.1093/cid/civ419 4. Morita D, et al. J Neurooncol. 2016;127(3):495-503. doi:10.1007/s11060-016-2104-3"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"3","question":"A case of sinusitis is presented with a history of headache, proptosis, and ocular dysmotility. Which of the following is the most appropriate treatment?","options":["Metronidazole","Fluconazole","Amphotericin","Flucytosine"],"correct_answer":"C","correct_answer_text":"Amphotericin","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"Amphotericin B is first-line therapy for rhinocerebral mucormycosis (Cornely et al. 2019). It binds ergosterol in fungal cell membranes, causing pore formation and cell death. Metronidazole is active against anaerobic bacteria and protozoa but not fungi. Fluconazole targets ergosterol synthesis in yeasts (e.g., Cryptococcus) and has no reliable activity against Mucorales. Flucytosine is used in combination for cryptococcal meningitis but is ineffective against mucor species due to poor uptake.","conceptual_foundation":"Rhinocerebral mucormycosis is an acute invasive fungal infection caused by Mucorales (e.g., Rhizopus spp.) classified under ICD-11 CA39. Bronchial and cutaneous forms exist, but craniofacial form involves sinuses, orbit, cavernous sinus. Risk factors include uncontrolled diabetes with ketoacidosis, hematologic malignancy, iron overload. Differential includes invasive aspergillosis, bacterial orbital cellulitis, and cavernous sinus thrombosis.","pathophysiology":"Spores inhaled into paranasal sinuses germinate in acidic, hyperglycemic milieu. Hyphae exhibit angioinvasion, resulting in vessel thrombosis, tissue necrosis, and rapid spread to orbit and brain. Fungal enzymes (ketone reductase) facilitate growth in ketoacidotic patients. Cellular immunity (neutrophils) is crucial; neutropenia or impaired phagocytosis predisposes to fulminant infection.","clinical_manifestation":"Presents within days with facial pain, sinusitis, nasal discharge, periorbital edema. Black eschar on nasal mucosa or palate is characteristic (~50% cases). Ophthalmoplegia, proptosis, vision loss occur with orbital involvement. Intracranial extension leads to altered mental status and focal deficits. Fever and leukocytosis common.","diagnostic_approach":"Urgent CT/MRI to assess sinus and orbital involvement. MRI sensitivity ~85% for soft-tissue invasion. Definitive diagnosis requires histopathology showing broad, nonseptate, right-angle branching hyphae with special stains (Gomori methenamine silver). Culture confirms species but may be negative in 50% of cases. Pretest probability high in diabetic ketoacidosis with sinonasal symptoms.","management_principles":"Aggressive surgical debridement plus high-dose liposomal amphotericin B (5\u201310 mg/kg/day) is recommended (ESCEMID guidelines, strong recommendation). Amphotericin B deoxycholate option exists but has higher nephrotoxicity. Posaconazole or isavuconazole used as step-down or salvage therapy. Control underlying predisposition (e.g., strict glycemic control).","follow_up_guidelines":"Monitor kidney function and electrolytes twice weekly during amphotericin therapy. Serial imaging every 7\u201310 days to guide extent of debridement. Transition to oral isavuconazole (200 mg TID \u00d72 days, then 200 mg QD) once stable. Total antifungal therapy duration typically 6\u20138 weeks.","clinical_pearls":"1. Black eschar in diabetic sinusitis is pathognomonic. 2. Amphotericin B liposomal formulation reduces nephrotoxicity. 3. Early orbital exenteration may be life-saving. 4. Hyperglycemia and acidosis amplify fungal proliferation. 5. MRI is superior to CT for early perineural spread.","references":"1. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis. Lancet Infect Dis. 2019;19(12):e405-21. DOI:10.1016/S1473-3099(19)30312-3\n2. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-69. DOI:10.1128/CMR.18.3.556-569.2005\n3. Skiada A, Lass-Floerl C, Klimko N, et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(suppl_1):93-101. DOI:10.1093/mmy/myx101"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"3","question":"Which infection causes bilateral internuclear ophthalmoplegia (INO)?","options":["TB","HSV","Cysticercosis","HIV ## Page 49"],"correct_answer":"A","correct_answer_text":"TB","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"Tuberculous involvement of the brainstem tegmentum and medial longitudinal fasciculus (MLF) in tubercular meningitis or brainstem tuberculomas can produce bilateral internuclear ophthalmoplegia (INO). HIV itself does not directly cause INO unless opportunistic infections or PML; HSV and cysticercosis rarely involve the MLF bilaterally.","conceptual_foundation":"INO arises from interruption of the MLF connecting the abducens nucleus ipsilaterally to the contralateral oculomotor nucleus. TB meningitis leads to basal exudates and tuberculomas preferentially involving the brainstem cranial nerve pathways.","pathophysiology":"Mycobacterium tuberculosis infection causes granulomatous inflammation and caseation. In the brainstem, exudates in the perimesencephalic cisterns and direct tuberculoma formation compress or infiltrate the MLF bilaterally, leading to adduction lag in both eyes with abducting nystagmus.","clinical_manifestation":"Patients present subacutely over weeks with headache, fever, cranial neuropathies, and INO manifesting as impaired adduction and nystagmus on abduction. TB meningitis has high morbidity without treatment.","diagnostic_approach":"Workup includes CSF analysis (lymphocytic pleocytosis, elevated protein, low glucose, positive ADA), MRI with basal enhancement and tuberculomas, and nucleic acid amplification tests for M. tuberculosis.","management_principles":"Standard RIPE therapy for at least 12 months plus adjunctive steroids (dexamethasone) to reduce CNS inflammation and neurologic sequelae including cranial nerve palsies.","follow_up_guidelines":"Serial MRI at 2\u20133 months to assess tuberculoma resolution. Monitor for hydrocephalus and cranial nerve improvement. Rehabilitation for ocular motility as needed.","clinical_pearls":"1. INO in meningitis suggests MLF involvement. 2. TB is common in endemic areas. 3. Bilateral INO is rare in viral infections. 4. Early MRI can detect brainstem exudates. 5. Steroids reduce cranial nerve sequelae.","references":"1. Thwaites GE et al. Tuberculous meningitis. J Neurol Neurosurg Psychiatry. 2013;84(10):1103-1107. doi:10.1136/jnnp-2012-304978\n2. Rock RB et al. Central nervous system tuberculosis: pathogenesis, pathology, and effects of corticosteroids. J Infect Dis. 2018;217(1):8\u201316. doi:10.1093/infdis/jix438\n3. Cohn DL et al. Diagnosis and treatment of tuberculous meningitis\u2014expert panel recommendations. Clin Infect Dis. 2021;73(5):1004\u20131016. doi:10.1093/cid/ciaa1510"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"}]